Genta has built a broad portfolio of proprietary products in various stages of clinical development. At Genta, we are aggressively leveraging our expertise in clinical oncology research by expanding and diversifying our R&D pipeline.
Genta is building a portfolio of products targeted against some of the most deadly cancers and related conditions facing patients today. With three products in the pipeline and ongoing trials in all phases of development (Preclinical to Phase 3), Genta is committed to developing innovative products to better the lives of people with cancer.
Latest Genta Announcements
Tesetaxel Clinical Status
How Oral Gallium Works